Praxis Precision Medicines, Inc. (PRAX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Marcio Silva De'Souza M.B.A. | President, CEO & Director | 1.18M | -- | 1980 |
| Mr. Timothy Edwin Kelly | CFO & Treasurer | 691.58k | -- | 1974 |
| Mr. Alex Nemiroff J.D. | General Counsel & Secretary | 577.34k | -- | 1980 |
| Dr. Steven Petrou B.Sc. (Hons.), Ph.D. | Co-Founder & Chief Scientific Officer | -- | -- | -- |
| Lauren Mastrocola | VP of Finance & Principal Accounting Officer | -- | -- | -- |
| Dr. Karl Hansen Ph.D. | Chief Technical Operations Officer | -- | -- | -- |
| Alex Kane | VP of Investor Relations & Corporate Communications | -- | -- | -- |
| Ms. Kelly McCue | Chief People Officer | -- | -- | -- |
| Ms. Alyssa J. S. Wyant | Chief Regulatory & Quality Officer | -- | -- | 1975 |
| Ms. Megan T. Sniecinski | Chief Business Officer | -- | -- | 1982 |
Praxis Precision Medicines, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 82
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Corporate Governance
Recent Events
- Mar 29, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 26, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 08, 2024CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submissionSee Full Filing
- Mar 05, 202410-K: Periodic Financial ReportsSee Full Filing
- Jan 31, 2024S-8: Offering RegistrationsSee Full Filing